ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Pao Named Director of Department Of Hematology And Oncology At Vanderbilt University

September 30, 2011

AACR, Kellogg’s Co. Sponsor Award

January 5, 1996

NCI-Approved CTEP Trials For the Month of December

December 28, 2012

NCI Pulls Back Curtain on “Zone of Uncertainty” — Funding Patterns Released With Little Comment

May 4, 2012

In Congress: Senate Committee Provides Increase To DOD Program

August 1, 1997

Chemoprevention, Immunotoxicolgy RFAs Available

June 5, 1981